主要文件

查看所有文档

D9571

Dolasetron mesylate hydrate

Name: Dolasetron mesylate hydrate
Brand: SIGMA

≥98% (HPLC), powder

别名:

Anzemet hydrate, Dolasetron methanesulfonate hydrate

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₂₀N₂O₃ · CH₄O₃S · xH₂O

化学文摘社编号:

115956-13-3

分子量:

420.48 (anhydrous basis)

MDL number:

MFCD30478915

UNSPSC Code:

12352200

PubChem Substance ID:

329798907

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

H₂O: >30 mg/mL

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

O.CS(O)(=O)=O.O=C1CN2[C@@H]3C[C@H](C[C@H]2CC1C3)OC(=O)c4c[nH]c5ccccc45

InChI

1S/C19H20N2O3.CH4O3S.H2O/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17;1-5(2,3)4;/h1-4,9,11-14,20H,5-8,10H2;1H3,(H,2,3,4);1H2/t11?,12-,13+,14+;;

InChI key

QTFFGPOXNNGTGZ-BHSFMSKKSA-N

说明

Biochem/physiol Actions

Dolasetron mesylate hydrate is a highly selective serotonin 5-HT3 receptor antagonist.

Dolasetron mesylate hydrate is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Serotonin Receptors

We offer many products related to serotonin receptors for your research needs.

血清素受体

我们提供许多血清素受体相关产品，满足您的各类研究需求。

Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.

Swen N Piper et al.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 36(3), 173-179 (2008-03-21)

The aim of this study was to evaluate the efficacy of dolasetron and droperidol (DHB) for preventing postoperative nausea and vomiting (PONV) in patients undergoing surgery for prognathism. In a randomised, placebo-controlled, double-blind trial, the efficacy of 12.5 mg dolasetron

The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting.

D Rüsch et al.

Anaesthesia, 62(8), 810-817 (2007-07-20)

It is not known whether dexamethasone increases the effectiveness of anti-emetics when given to treat postoperative nausea and vomiting (PONV). In a randomised study, 242 patients who were experiencing PONV received dolasetron and placebo, haloperidol and placebo, dolasetron and dexamethasone

5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities.

Sadeq A Quraishi et al.

Journal of clinical anesthesia, 23(4), 297-302 (2011-06-15)

To investigate whether a common single nucleotide polymorphism (SNP), rs10494366, is associated with significant prolongation of the QTc interval following administration of 5-HT(3)-receptor antagonists in the perioperative setting. Post-hoc analysis of deoxyribonucleic acid (DNA) samples and electrocardiographic (ECG) data from

查看所有相关文献

全球贸易项目编号

货号	GTIN
D9571-50MG	04061832082042
D9571-10MG	04061832082035